Literature DB >> 11413048

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in atherogenesis.

N Kume1, T Kita.   

Abstract

Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-II membrane protein belonging to the C-type lectin family molecules, which can act as a cell surface endocytosis receptor for atherogenic oxidized LDL (Ox-LDL). LOX-1 is synthesized as a 40 kDa precursor protein with N-linked high mannose-type carbohydrate, which is further glycosylated and processed into a 50 kDa mature form. LOX-1 expression is not constitutive but can be induced by proinflammatory, oxidative, and mechanical stimuli. In addition to endothelial cells, macrophages and activated vascular smooth muscle cells express LOX-1. In vivo, endothelial cells covering early atherosclerotic lesions and macrophages and smooth muscle cells accumulated in the intima of advanced atherosclerotic plaques express LOX-1. LOX-1 is cleaved at membrane proximal extracellular domain by some protease activities and released from the cell surface. Measurement of soluble LOX-1 in vivo may provide novel diagnostic strategy for the evaluation and prediction of atherosclerosis and vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413048     DOI: 10.1016/s1050-1738(01)00079-2

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  16 in total

1.  The lectin-like oxidized low-density lipoprotein receptor and its role in atherosclerosis.

Authors:  Mehmet Cilingiroglu; Kerem Ozer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 2.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 3.  Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis.

Authors:  Sanjiv Singh; Avtar Singh Gautam
Journal:  Curr Atheroscler Rep       Date:  2019-07-27       Impact factor: 5.113

Review 4.  Mechanisms of foam cell formation in atherosclerosis.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  J Mol Med (Berl)       Date:  2017-08-07       Impact factor: 4.599

Review 5.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

6.  Pathological and molecular analyses of atherosclerotic lesions in ApoE-knockout mice.

Authors:  Masa-Aki Shibata; Eiko Shibata; Kentaro Maemura; Yoichi Kondo; Mariko Harada-Shiba
Journal:  Med Mol Morphol       Date:  2017-02-28       Impact factor: 2.309

Review 7.  LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.

Authors:  Suowen Xu; Sayoko Ogura; Jiawei Chen; Peter J Little; Joel Moss; Peiqing Liu
Journal:  Cell Mol Life Sci       Date:  2012-11-03       Impact factor: 9.261

8.  Effects of hydrogen as adjuvant treatment for unstable angina.

Authors:  Yanhong Si; Hua Tian; Bingqing Dong; Ying Zhang; Yuanyuan Wen; Xiubin Jia; Ying Li; Aihua Zhang; Shucun Qin
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-25

9.  Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis.

Authors:  Jenny Jongstra-Bilen; Mehran Haidari; Su-Ning Zhu; Mian Chen; Daipayan Guha; Myron I Cybulsky
Journal:  J Exp Med       Date:  2006-08-07       Impact factor: 14.307

10.  Vitamin D3 Induces Gene Expression of Ox-LDL Scavenger Receptors in Streptozotocin-Induced Diabetic Rat Aortas: New Insight into the Role of Vitamin D in Diabetic Atherosclerosis.

Authors:  Shahab Alizadeh; Abbas Mirshafiey; Mahmoud Djalali; Ehsan Alvandi; Niyaz Mohammadzadeh Honarvar; Mohammad Hassan Javanbakht
Journal:  Rep Biochem Mol Biol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.